87536

Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification

CPT code 87536 describes the sophisticated laboratory procedure for the quantitative detection of Human Immunodeficiency Virus Type 1 (HIV-1) nucleic acid (RNA) in a patient specimen, most typically utilizing blood plasma or serum. This diagnostic assay is commonly referred to in clinical practice as an HIV-1 viral load test. The procedure begins with the safe collection, handling, and preparation of the patient's venous blood sample, from which the viral RNA is carefully extracted, isolated, and purified using advanced laboratory methodologies. Because the human immunodeficiency virus is an RNA-based retrovirus, the extracted viral RNA must first be reverse-transcribed into complementary DNA (cDNA) using a specialized enzyme known as reverse transcriptase. Following this crucial conversion step, the synthesized cDNA is subjected to highly sensitive nucleic acid amplification testing (NAAT). The most frequently utilized techniques for this amplification include real-time Polymerase Chain Reaction (RT-PCR), transcription-mediated amplification (TMA), or branched DNA (bDNA) signal amplification methodologies. During a real-time PCR assay, fluorescently labeled oligonucleotide probes bind to specific, highly conserved genomic target regions of the HIV-1 virus. As the thermal cycling amplification cycles progress, the corresponding increase in fluorescent signal is measured in real-time by the laboratory instrument's optical system. The integrated proprietary software then accurately calculates the exact quantity of HIV-1 RNA present in the original patient sample by directly comparing the fluorescent signal intensity to a standardized calibration curve generated from known concentrations of viral RNA. The final laboratory result is meticulously reported in copies of HIV-1 RNA per milliliter (copies/mL) of blood. This exact quantitative measurement is an absolutely indispensable tool in modern infectious disease clinical management. It empowers clinicians to establish accurate baseline viral load measurements before the initiation of highly active antiretroviral therapy (HAART), to routinely monitor the patient's ongoing physiological response to the prescribed antiviral medication regimen, to quickly detect early treatment failure, medication non-adherence, or viral rebound phenomena, and to comprehensively assess the patient's long-term risk of immunological decline, disease progression, or potential viral transmission to others. The exquisite molecular sensitivity of this advanced assay permits the reliable detection of very low levels of circulating virus, frequently measuring down to 20 copies/mL or fewer, thereby playing a critical and central role in achieving and sustaining durable viral suppression in patients living with HIV-1.

Clinical Indications

  • Baseline quantification of HIV-1 viral load prior to the initiation of highly active antiretroviral therapy (HAART).
  • Routine clinical monitoring of virologic response to antiretroviral therapy to ensure sustained viral suppression.
  • Investigation of suspected antiretroviral treatment failure, indicated by clinical decline or immunological deterioration.
  • Detection and confirmation of viral rebound in patients previously suppressed on antiretroviral therapy.
  • Routine monitoring of patients living with HIV-1 who are not currently receiving antiretroviral therapy to assess the risk of disease progression.
  • Evaluation of the risk of vertical transmission from an HIV-positive pregnant woman to her fetus to guide perinatal management.
  • Diagnosis of acute HIV-1 infection in high-risk patients suspected of acute retroviral syndrome prior to antibody seroconversion.

Procedure Steps

  1. Collection of the patient's venous blood specimen into an appropriate collection tube, most commonly an EDTA preparation.
  2. Centrifugation of the collected blood sample to cleanly separate the plasma from the cellular components.
  3. Addition of a specialized lysis buffer to the isolated plasma to chemically disrupt viral particles and release the HIV-1 RNA.
  4. Extraction and purification of the targeted viral RNA utilizing magnetic bead-based or spin-column-based laboratory technologies.
  5. Introduction of target-specific oligonucleotide primers, fluorescent probes, and critical enzymes including reverse transcriptase and DNA polymerase.
  6. Reverse transcription of the extracted and purified HIV-1 RNA into stable complementary DNA (cDNA).
  7. Amplification of the target cDNA sequences utilizing real-time polymerase chain reaction (RT-PCR) or alternative approved nucleic acid amplification techniques.
  8. Continuous real-time optical monitoring of fluorescent signal emission that corresponds proportionally to the amount of amplified viral nucleic acid.
  9. Algorithmic calculation of the initial viral concentration by plotting the specific amplification curve against a standardized instrument calibration curve.
  10. Verification of built-in internal controls to definitively confirm efficient RNA extraction and the complete absence of PCR inhibitors in the sample.
  11. Final quantitative reporting of the HIV-1 viral load to the ordering clinician in copies per milliliter (copies/mL).

Coding Guidelines

  • Report CPT code 87536 specifically for the absolute quantification of HIV-1 nucleic acid, commonly known as an HIV-1 viral load test.
  • Do not use CPT 87536 for the simple qualitative detection of HIV-1; use CPT 87535 if the test only reports positive or negative results.
  • Do not report CPT 87536 in conjunction with direct probe technique CPT 87534 for the same infectious agent.
  • CPT 87536 is specific to HIV-1. For the quantitative testing of HIV-2, report CPT code 87539 instead.
  • Ensure documentation explicitly demonstrates the medical necessity for viral load quantification, supported by accurate ICD-10-CM diagnosis codes such as B20 or Z21.
  • If multiple distinct nucleic acid amplification tests are performed for entirely different infectious agents on the same date of service, report each specific CPT code separately.
  • Routine screening of asymptomatic patients without known HIV infection typically utilizes alternative qualitative testing codes rather than quantitative code 87536.

Associated ICD-10 Codes